Cullinan Therapeutics, Inc.
CGEM
$8.74
-$0.33-3.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.56% | -100.17% | -3.51% | -30.47% | 35.91% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -5.00% | -4.94% | 5.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.36% | 167.96% | -12.44% | 17.89% | -17.22% |
| Change in Net Operating Assets | 69.63% | 45.65% | 1,117.68% | 75.30% | -600.34% |
| Cash from Operations | -12.83% | -102.01% | 0.01% | -17.05% | 25.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 184.08% | -68.98% | 146.27% | -1,622.43% | -15.56% |
| Cash from Investing | 184.08% | -68.98% | 146.27% | -1,628.59% | -14.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 537.90% | 1,668.75% | 589.70% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -10,633.33% | -- |
| Cash from Financing | -- | 537.90% | 1,083.04% | 579.23% | -39.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.77% | -156.81% | 83.20% | 107.01% | 28.86% |